Blair William & Co. IL Has $30.51 Million Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Blair William & Co. IL has reduced its stake in Edwards Lifesciences Corporation by 7.2% in Q2, now holding $30.51 million worth of shares after selling 30,093 shares.
• Insider Larry L. Wood sold 8,950 shares at $78.06 each, resulting in a total transaction value of $698,637, decreasing his ownership by 4.15%.
• Edwards Lifesciences reported quarterly earnings of $0.67 EPS, exceeding both last year's results and analysts' expectations, with revenues rising 11.9% year-over-year.

Blair William & Co. IL lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 7.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 390,133 shares of the medical research company's stock after selling 30,093 shares during the quarter. Blair William & Co. IL owned about 0.07% of Edwards Lifesciences worth $30,512,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $27,000. Global X Japan Co. Ltd. grew its holdings in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the period. Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Finally, Rossby Financial LCC acquired a new stake in Edwards Lifesciences in the first quarter worth $29,000. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.17 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a 50-day moving average of $78.20 and a 200-day moving average of $76.08. The stock has a market capitalization of $44.13 billion, a price-to-earnings ratio of 10.82, a PEG ratio of 3.64 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on EW. Oppenheimer lowered shares of Edwards Lifesciences from an "outperform" rating to a "market perform" rating in a report on Wednesday. Wall Street Zen downgraded Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a report on Monday, September 29th. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft boosted their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Finally, Piper Sandler raised their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $87.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.